PPT-Cardiovascular Health & Diabetes:

A Public Health Role for Minnesota Pharmacists James Peacock PhD MPH PROTECTING MAINTAINING AND IMPROVING THE HEALTH OF ALL MINNESOTANS Cardiovascular Disease amp Diabetes in Minnesota Heart Disease 2. Applying evidence based medicine to clinical care. Cardiovascular disease is the biggest killer in UK. Number. of . deaths. (000’s). 124,037. 60,666. 18,165. 33,634. 16,216. 12,762. 103,431. 19,996. Public Health . (31505291). الصحة . العامة. Lecture 17. The global health impact of Cardiovascular Diseases , Diabetes and Obesity. By . Hatim. . Jaber. MD MPH JBCM PhD. 30 - 7-2018. 1. Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. European Association for the Study of Diabetes. Lisbon, . 13. th. . September 2017. ISRCTN number: 91899513. ClinicalTrials.gov number: . NCT00829660. Study Rationale, Design and Conduct. The Diabetes Burden. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . 298.8518.0292.1727.4 Mortality from CVD (OECD) Mortality from all other causes (OECD) Mortality from CVD (Mexico) Mortality from all other causes (Mexico)Age-standardised rates per 100 000 population Jan - March 201 8 ; 5 ( 1 ): 2 3 - 2 9 Page 23 www.ijmse.com International Journal of Medical Science and Education An official Publication of Association for Scientific and Medical Education (ASME TECOS Executive Committee MemberRury R. Holman, MB, ChBDiabetes Trials Unit, OCDEM Churchill Hospital, Oxford, United KingdomTECOS CoPrincipal Investigator andJoint Chair of TECOS Executive CommitteeR According to the national health survey (DEGS1), the rate is 7.2% in 2014. 298.8518.0310.2476.6 Mortality from CVD (OECD) Mortality from all other causes (OECD)Age-standardised rates per 100 000 po Sex . Male. Diabetes. . History. T2D, . onset. @45 . yrs. , treatment: . metformin. , . sitagliptin. and . gliclazide. . Organ. . damage. . evaluation. :. Eyes. : No . signs. of . retinopathy. January 24, 2023. Mary Pesik. Chronic Disease Prevention Program Director. Welcome. 2. Today’s Agenda. 3. 2023 Centers for Disease Control and Prevention (CDC) Notice of Funding Opportunities. Prediabetes and Diabetes. Lexi Davis, Healthy Communities Coordinator. Anne Gargano Ahmed, Heart Health Coordinator. November 9, 2022 . November 17, 2022. CDC Grant Opportunity Forecasts. Chronic Disease Prevention Program. Agenda and Purpose. GGC MCN meeting 5. th. February 2019. John R Petrie. Professor of Diabetic Medicine. University of Glasgow, UK. Advisory and Consultancy Work:. Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, . Servier.